Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis

Corina N. D'Alessandro-Gabazza; Tetsu Kobayashi; Daniel Boveda-Ruiz; Takehiro Takagi; Masaaki Toda; Paloma Gil-Bernabe; Yasushi Miyake; Atsushi Yasukawa; Yoshikazu Matsuda; Noboru Suzuki; Hiromitsu Saito; Yutaka Yano; Ayako Fukuda; Tetsuya Hasegawa; Hidekazu Toyobuku; Stephen I. Rennard; Peter D. Wagner; John Morser; Yoshiyuki Takei; Osamu Taguchi; Esteban C. Gabazza

doi:10.1165/rcmb.2011-0158OC

Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis

Corina N. D'Alessandro-Gabazza, Tetsu Kobayashi, Daniel Boveda-Ruiz, Takehiro Takagi, Masaaki Toda, Paloma Gil-Bernabe, Yasushi Miyake, Atsushi Yasukawa, Yoshikazu Matsuda, Noboru Suzuki, Hiromitsu Saito, Yutaka Yano, Ayako Fukuda, Tetsuya Hasegawa, Hidekazu Toyobuku, Stephen I. Rennard, Peter D. Wagner, John Morser, Yoshiyuki Takei, Osamu TaguchiEsteban C. Gabazza

Pulmonary, Critical Care, & Sleep Medicine

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Idiopathic pulmonary fibrosis is a chronic devastating disease of unknown etiology.Notherapy is currently available.Agrowingbody of evidence supports the role of transforming growth factor (TGF)- β1 as the major player in the pathogenesis of the disease. However, attempts to control its expression and to improve the outcome of pulmonary fibrosis have been disappointing. We tested the hypothesis that TGF-β1 is the dominant factor in the acute and chronic phases of pulmonary fibrosis and developed short interfering (si) RNAsdirectedtowardmolecules implicated in the disease. This study developed novel sequences of siRNAs targeting the TGF-β1 gene and evaluated their therapeutic efficacy in two models of pulmonary fibrosis: a model induced by bleomycin and a novel model of the disease developed spontaneously in mice overexpressing the full length of human TGF-β1 in the lungs. Intrapulmonary delivery of aerosolized siRNAs of TGF-β1 with sequences common to humans and rodents significantly inhibited bleomycin-induced pulmonary fibrosis in the acute and chronic phases of the disease and in a dose-dependent manner. Aerosolized human-specific siRNA also efficiently inhibited pulmonary fibrosis, improvedlung function,andprolonged survival in human TGF-β1 transgenic mice. Mice showed no off-target effects after intratracheal administration of siRNA. These results suggest the applicability of these novel siRNAs as tools for treating pulmonary fibrosis in humans.

Original language	English (US)
Pages (from-to)	397-406
Number of pages	10
Journal	American journal of respiratory cell and molecular biology
Volume	46
Issue number	3
DOIs	https://doi.org/10.1165/rcmb.2011-0158OC
State	Published - Mar 1 2012

Keywords

Growth factors
Idiopathic pulmonary fibrosis
RNA interference

ASJC Scopus subject areas

Molecular Biology
Pulmonary and Respiratory Medicine
Clinical Biochemistry
Cell Biology

Access to Document

10.1165/rcmb.2011-0158OC

Fingerprint Dive into the research topics of 'Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis'. Together they form a unique fingerprint.

Cite this

D'Alessandro-Gabazza, C. N., Kobayashi, T., Boveda-Ruiz, D., Takagi, T., Toda, M., Gil-Bernabe, P., Miyake, Y., Yasukawa, A., Matsuda, Y., Suzuki, N., Saito, H., Yano, Y., Fukuda, A., Hasegawa, T., Toyobuku, H., Rennard, S. I., Wagner, P. D., Morser, J., Takei, Y., ... Gabazza, E. C. (2012). Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. American journal of respiratory cell and molecular biology, 46(3), 397-406. https://doi.org/10.1165/rcmb.2011-0158OC

Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. / D'Alessandro-Gabazza, Corina N.; Kobayashi, Tetsu; Boveda-Ruiz, Daniel; Takagi, Takehiro; Toda, Masaaki; Gil-Bernabe, Paloma; Miyake, Yasushi; Yasukawa, Atsushi; Matsuda, Yoshikazu; Suzuki, Noboru; Saito, Hiromitsu; Yano, Yutaka; Fukuda, Ayako; Hasegawa, Tetsuya; Toyobuku, Hidekazu; Rennard, Stephen I.; Wagner, Peter D.; Morser, John; Takei, Yoshiyuki; Taguchi, Osamu; Gabazza, Esteban C.

In: American journal of respiratory cell and molecular biology, Vol. 46, No. 3, 01.03.2012, p. 397-406.

Research output: Contribution to journal › Article › peer-review

D'Alessandro-Gabazza, CN, Kobayashi, T, Boveda-Ruiz, D, Takagi, T, Toda, M, Gil-Bernabe, P, Miyake, Y, Yasukawa, A, Matsuda, Y, Suzuki, N, Saito, H, Yano, Y, Fukuda, A, Hasegawa, T, Toyobuku, H, Rennard, SI, Wagner, PD, Morser, J, Takei, Y, Taguchi, O & Gabazza, EC 2012, 'Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis', American journal of respiratory cell and molecular biology, vol. 46, no. 3, pp. 397-406. https://doi.org/10.1165/rcmb.2011-0158OC

D'Alessandro-Gabazza, Corina N. ; Kobayashi, Tetsu ; Boveda-Ruiz, Daniel ; Takagi, Takehiro ; Toda, Masaaki ; Gil-Bernabe, Paloma ; Miyake, Yasushi ; Yasukawa, Atsushi ; Matsuda, Yoshikazu ; Suzuki, Noboru ; Saito, Hiromitsu ; Yano, Yutaka ; Fukuda, Ayako ; Hasegawa, Tetsuya ; Toyobuku, Hidekazu ; Rennard, Stephen I. ; Wagner, Peter D. ; Morser, John ; Takei, Yoshiyuki ; Taguchi, Osamu ; Gabazza, Esteban C. / Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. In: American journal of respiratory cell and molecular biology. 2012 ; Vol. 46, No. 3. pp. 397-406.

@article{30fe5fa96b3f4956be48a92c2c8fdbaa,

title = "Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis",

abstract = "Idiopathic pulmonary fibrosis is a chronic devastating disease of unknown etiology.Notherapy is currently available.Agrowingbody of evidence supports the role of transforming growth factor (TGF)- β1 as the major player in the pathogenesis of the disease. However, attempts to control its expression and to improve the outcome of pulmonary fibrosis have been disappointing. We tested the hypothesis that TGF-β1 is the dominant factor in the acute and chronic phases of pulmonary fibrosis and developed short interfering (si) RNAsdirectedtowardmolecules implicated in the disease. This study developed novel sequences of siRNAs targeting the TGF-β1 gene and evaluated their therapeutic efficacy in two models of pulmonary fibrosis: a model induced by bleomycin and a novel model of the disease developed spontaneously in mice overexpressing the full length of human TGF-β1 in the lungs. Intrapulmonary delivery of aerosolized siRNAs of TGF-β1 with sequences common to humans and rodents significantly inhibited bleomycin-induced pulmonary fibrosis in the acute and chronic phases of the disease and in a dose-dependent manner. Aerosolized human-specific siRNA also efficiently inhibited pulmonary fibrosis, improvedlung function,andprolonged survival in human TGF-β1 transgenic mice. Mice showed no off-target effects after intratracheal administration of siRNA. These results suggest the applicability of these novel siRNAs as tools for treating pulmonary fibrosis in humans.",

keywords = "Growth factors, Idiopathic pulmonary fibrosis, RNA interference",

author = "D'Alessandro-Gabazza, {Corina N.} and Tetsu Kobayashi and Daniel Boveda-Ruiz and Takehiro Takagi and Masaaki Toda and Paloma Gil-Bernabe and Yasushi Miyake and Atsushi Yasukawa and Yoshikazu Matsuda and Noboru Suzuki and Hiromitsu Saito and Yutaka Yano and Ayako Fukuda and Tetsuya Hasegawa and Hidekazu Toyobuku and Rennard, {Stephen I.} and Wagner, {Peter D.} and John Morser and Yoshiyuki Takei and Osamu Taguchi and Gabazza, {Esteban C.}",

year = "2012",

month = mar,

day = "1",

doi = "10.1165/rcmb.2011-0158OC",

language = "English (US)",

volume = "46",

pages = "397--406",

journal = "American Journal of Respiratory Cell and Molecular Biology",

issn = "1044-1549",

publisher = "American Thoracic Society",

number = "3",

}

TY - JOUR

T1 - Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis

AU - D'Alessandro-Gabazza, Corina N.

AU - Kobayashi, Tetsu

AU - Boveda-Ruiz, Daniel

AU - Takagi, Takehiro

AU - Toda, Masaaki

AU - Gil-Bernabe, Paloma

AU - Miyake, Yasushi

AU - Yasukawa, Atsushi

AU - Matsuda, Yoshikazu

AU - Suzuki, Noboru

AU - Saito, Hiromitsu

AU - Yano, Yutaka

AU - Fukuda, Ayako

AU - Hasegawa, Tetsuya

AU - Toyobuku, Hidekazu

AU - Rennard, Stephen I.

AU - Wagner, Peter D.

AU - Morser, John

AU - Takei, Yoshiyuki

AU - Taguchi, Osamu

AU - Gabazza, Esteban C.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Idiopathic pulmonary fibrosis is a chronic devastating disease of unknown etiology.Notherapy is currently available.Agrowingbody of evidence supports the role of transforming growth factor (TGF)- β1 as the major player in the pathogenesis of the disease. However, attempts to control its expression and to improve the outcome of pulmonary fibrosis have been disappointing. We tested the hypothesis that TGF-β1 is the dominant factor in the acute and chronic phases of pulmonary fibrosis and developed short interfering (si) RNAsdirectedtowardmolecules implicated in the disease. This study developed novel sequences of siRNAs targeting the TGF-β1 gene and evaluated their therapeutic efficacy in two models of pulmonary fibrosis: a model induced by bleomycin and a novel model of the disease developed spontaneously in mice overexpressing the full length of human TGF-β1 in the lungs. Intrapulmonary delivery of aerosolized siRNAs of TGF-β1 with sequences common to humans and rodents significantly inhibited bleomycin-induced pulmonary fibrosis in the acute and chronic phases of the disease and in a dose-dependent manner. Aerosolized human-specific siRNA also efficiently inhibited pulmonary fibrosis, improvedlung function,andprolonged survival in human TGF-β1 transgenic mice. Mice showed no off-target effects after intratracheal administration of siRNA. These results suggest the applicability of these novel siRNAs as tools for treating pulmonary fibrosis in humans.

AB - Idiopathic pulmonary fibrosis is a chronic devastating disease of unknown etiology.Notherapy is currently available.Agrowingbody of evidence supports the role of transforming growth factor (TGF)- β1 as the major player in the pathogenesis of the disease. However, attempts to control its expression and to improve the outcome of pulmonary fibrosis have been disappointing. We tested the hypothesis that TGF-β1 is the dominant factor in the acute and chronic phases of pulmonary fibrosis and developed short interfering (si) RNAsdirectedtowardmolecules implicated in the disease. This study developed novel sequences of siRNAs targeting the TGF-β1 gene and evaluated their therapeutic efficacy in two models of pulmonary fibrosis: a model induced by bleomycin and a novel model of the disease developed spontaneously in mice overexpressing the full length of human TGF-β1 in the lungs. Intrapulmonary delivery of aerosolized siRNAs of TGF-β1 with sequences common to humans and rodents significantly inhibited bleomycin-induced pulmonary fibrosis in the acute and chronic phases of the disease and in a dose-dependent manner. Aerosolized human-specific siRNA also efficiently inhibited pulmonary fibrosis, improvedlung function,andprolonged survival in human TGF-β1 transgenic mice. Mice showed no off-target effects after intratracheal administration of siRNA. These results suggest the applicability of these novel siRNAs as tools for treating pulmonary fibrosis in humans.

KW - Growth factors

KW - Idiopathic pulmonary fibrosis

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=84863281562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863281562&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2011-0158OC

DO - 10.1165/rcmb.2011-0158OC

M3 - Article

C2 - 22033267

AN - SCOPUS:84863281562

VL - 46

SP - 397

EP - 406

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 3

ER -

Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this